ANAPTYSBIO, INC

ANAB

ANAPTYSBIO, INC

ANAB

Insider Sentiment (TTM):

Last Purchase:2025-01-02Last Sale:2026-03-30Shares Purchased (TTM):0Shares Sold (TTM):180,344

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:28,029,935Shares Outstanding:28,691,000Institutional Ownership Pct.:97.70%

Earnings Market Reaction:

Filing Date:2026-05-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	248	238	110	44	99	123	192	72	54	36	26	35
Receivables Net Current	26	34	76	21	18	41	12	9	7	7	3	3
Available For Sale Securities Debt Securities Curr…	38	73	139	221	241	262	239	279	301	355	387	394
Prepaid Expense And Other Assets Current	4	5	6	5	5	6	6	8	11	9	12	6
Assets Current	316	350	331	292	363	432	449	367	372	407	428	439
Property Plant And Equipment Net	1	1	2	2	2	2	2	2	2	2	2	2
Operating Lease Right Of Use Asset	12	13	13	13	14	14	15	15	16	16	17	17
Available For Sale Securities Debt Securities Nonc…	-	0	8	28	43	35	28	43	15	27	40	59
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	330	364	353	335	422	484	493	427	406	452	487	517
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	8	4	3	3	6	4	4	5	5	5	7	5
Accrued Liabilities Current	32	33	33	30	36	40	38	34	26	31	31	35
Operating Lease Liability Current	2	2	2	2	2	2	2	2	2	2	2	2
Liabilities Current	42	39	38	36	44	45	44	40	32	37	39	42
Operating Lease Liability Noncurrent	11	12	13	13	14	14	15	15	16	16	16	17
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	838	810	793	793	832	830	821	715	706	703	695	687
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	-0	0	0	1	-0	-1	-1	-2	-4
Retained Earnings Accumulated Deficit	-825	-773	-822	-837	-799	-759	-738	-705	-658	-614	-572	-535
Stockholders Equity	13	37	-29	-45	34	71	84	10	48	88	120	148
Liabilities And Stockholders Equity	330	364	353	335	422	484	493	427	406	452	487	517
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	500	500	500	500	500	500	500	500	500	500	500	500
Common Stock Shares Issued	29	28	28	28	30	30	30	27	27	27	27	27
Shares Outstanding	29	28	28	28	30	30	30	27	27	27	27	27

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-23.19%	-3.29%	-18.63%	-	-	-	-	-	-	-	-	-
2025	7.24%	8.39%	29.96%	-9.80%	4.61%	55.59%	19.89%	44.21%	36.85%	8.65%	67.18%	69.53%
2024	-8.73%	-4.46%	41.29%	17.67%	-1.54%	-1.05%	25.55%	-34.41%	-15.24%	4.15%	25.30%	23.29%
2023	-	-	-	6.72%	-2.71%	-11.43%	-11.79%	28.02%	44.88%	-9.72%	13.83%	2.53%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	7.58	9.07	8.68	8.22	8.25	9.51	10.23	9.09	11.53	10.87	10.92	10.53
Quick Ratio	7.49	8.94	8.52	8.08	8.13	9.38	10.08	8.90	11.20	10.62	10.63	10.39
Working Capital	274.41M	311.63M	292.55M	256.38M	319.08M	386.45M	404.80M	326.93M	340.12M	369.39M	388.82M	396.90M
Leverage & Debt
Debt to Equity	3.27	1.04	-1.30	-0.79	1.29	0.64	0.52	4.09	0.68	0.42	0.33	0.28
Debt Ratio	0.13	0.11	0.11	0.11	0.10	0.09	0.09	0.09	0.08	0.08	0.08	0.08
Efficiency & Turnover
Asset Turnover TTM	0.62	0.55	0.40	0.32	0.27	0.19	0.12	0.06	0.05	0.03	0.03	0.02
Days Sales Outstanding TTM	34.26	58.04	94.64	45.08	40.74	95.20	49.36	73.00	68.45	87.97	54.27	59.47
Receivables Turnover TTM	10.65	6.29	3.86	8.10	8.96	3.83	7.39	5.00	5.33	4.15	6.73	6.14
Per Share Metrics
Diluted EPS TTM	-0.93	-0.46	-2.92	-4.60	-4.59	-5.12	-5.73	-6.22	-6.09	-6.08	-5.57	-5.41
Free Cash Flow Per Share TTM	0.15	0.68	-5.22	-4.45	-3.56	-4.78	-3.58	-4.75	-5.01	-4.52	-3.69	-2.97
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	17.56%	20.42%	-16.92%	-69.94%	-89.64%	-125.93%	-257.84%	-532.89%	-706.43%	-958.27%	-990.97%	-1,083.49%
Net Profit Margin TTM	-11.53%	-5.64%	-49.94%	-107.66%	-125.70%	-159.10%	-289.75%	-558.25%	-711.17%	-953.66%	-988.11%	-1,113.37%
Growth Metrics
Net Revenue Growth (1Y)	107.73%	157.01%	196.42%	304.17%	387.20%	432.03%	282.17%	135.59%	114.78%	66.78%	233.18%	-46.30%
Net Income Growth (1Y)	-80.95%	-90.89%	-48.91%	-22.06%	-13.89%	-11.24%	12.07%	18.12%	19.44%	27.11%	9.62%	33.33%
EPS Growth (1Y)	-79.65%	-91.01%	-46.97%	-25.99%	-24.69%	-15.80%	2.96%	14.98%	24.57%	32.97%	16.82%	41.22%
Valuation Metrics
P/E TTM	-39.60	-70.24	-6.71	-3.22	-2.70	-1.72	-3.90	-2.69	-2.46	-2.35	-2.15	-2.51
P/B TTM	83.22	24.98	-19.31	-9.53	11.16	3.54	7.65	46.26	8.42	4.36	2.64	2.43
P/S TTM	4.56	3.96	3.35	3.46	3.39	2.74	11.29	15.00	17.52	22.41	21.25	27.92
Market Cap	1.06B	929.46M	568.16M	426.39M	379.78M	250.52M	645.28M	457.03M	402.37M	384.47M	317.84M	361.09M
Enterprise Value	812.33M	944.03M	458.33M	382.09M	281.14M	127.44M	453.70M	385.21M	348.68M	348.51M	291.55M	325.88M
Calculated Values
Free Cash Flow TTM	4.41M	19.61M	-145.32M	-128.08M	-109.15M	-135.70M	-103.39M	-129.90M	-134.14M	-121.61M	-97.84M	-79.00M
Net Debt	-248.47M	14.57M	-109.83M	-44.30M	-98.64M	-123.08M	-191.58M	-71.82M	-53.70M	-35.97M	-26.30M	-35.21M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-03-30Sale

Owner: Schmid, John P.

Title: -

Shares: 20,645

Price/Share: $56.60

Value: $1,168,507.00

Shares Owned: 31,622

Relationship: Director

Ownership: Direct

2026-03-27Sale

Owner: Faga, Daniel

Title: President, CEO

Shares: 17,679

Price/Share: $61.43

Value: $1,086,020.97

Shares Owned: 495,965

Relationship: Director,Officer

Ownership: Direct

2026-02-11Sale

Owner: Loumeau, Eric J

Title: CHIEF LEGAL OFFICER

Shares: 10,000

Price/Share: $54.00

Value: $540,000.00

Shares Owned: 12,835

Relationship: Officer

Ownership: Direct

2026-01-15Sale

Owner: Marquet, Magda

Title: -

Shares: 11,000

Price/Share: $48.48

Value: $533,280.00

Shares Owned: 9,930

Relationship: Director

Ownership: Direct

2026-01-08Sale

Owner: Mulroy, Dennis

Title: CHIEF FINANCIAL OFFICER

Shares: 2,515

Price/Share: $44.71

Value: $112,445.65

Shares Owned: 21,852

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-03-30	Schmid, John P.	Director	-	Direct	Sale	20,645	56.60	$1,168,507.00	31,622	4
2026-03-27	Faga, Daniel	Director,Officer	President, CEO	Direct	Sale	17,679	61.43	$1,086,020.97	495,965	4
2026-02-11	Loumeau, Eric J	Officer	CHIEF LEGAL OFFICER	Direct	Sale	10,000	54.00	$540,000.00	12,835	4
2026-01-15	Marquet, Magda	Director	-	Direct	Sale	11,000	48.48	$533,280.00	9,930	4
2026-01-08	Mulroy, Dennis	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	2,515	44.71	$112,445.65	21,852	4
2026-01-08	Faga, Daniel	Director,Officer	President, CEO	Direct	Sale	14,281	44.71	$638,503.51	479,344	4
2026-01-08	Loumeau, Eric J	Officer	CHIEF LEGAL OFFICER	Direct	Sale	2,210	44.71	$98,809.10	12,835	4
2026-01-08	Lizzul, Paul F.	Officer	Chief Medical Officer	Direct	Sale	3,650	44.71	$163,191.50	42,088	4
2026-01-07	Mulroy, Dennis	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,908	45.11	$86,069.88	17,667	4
2026-01-07	Lizzul, Paul F.	Officer	Chief Medical Officer	Direct	Sale	2,235	45.11	$100,820.85	37,213	4
2026-01-07	Loumeau, Eric J	Officer	CHIEF LEGAL OFFICER	Direct	Sale	9,639	45.96	$443,008.44	9,157	4
2026-01-07	Faga, Daniel	Director,Officer	President, CEO	Direct	Sale	9,202	45.11	$415,102.22	466,787	4
2026-01-05	Loumeau, Eric J	Officer	CHIEF LEGAL OFFICER	Direct	Sale	2,983	43.26	$129,044.58	13,251	4
2026-01-05	Lizzul, Paul F.	Officer	Chief Medical Officer	Direct	Sale	4,219	43.26	$182,513.94	33,303	4
2026-01-05	Mulroy, Dennis	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,363	43.26	$145,483.38	14,330	4
2026-01-05	Faga, Daniel	Director,Officer	President, CEO	Direct	Sale	15,309	43.26	$662,267.34	458,139	4
2025-12-23	Ware, J. Anthony	Director	-	Direct	Sale	3,900	49.58	$193,362.00	9,630	4
2025-12-22	Loumeau, Eric J	Officer	CHIEF LEGAL OFFICER	Direct	Sale	10,000	51.00	$510,000.00	8,947	4
2025-12-22	Mulroy, Dennis	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	10,000	50.00	$500,000.00	9,401	4
2025-12-22	Lizzul, Paul F.	Officer	Chief Medical Officer	Direct	Sale	1,500	50.00	$75,000.00	26,967	4
2025-12-18	Loumeau, Eric J	Officer	CHIEF LEGAL OFFICER	Direct	Sale	141	46.99	$6,625.59	8,947	4
2025-12-16	Mulroy, Dennis	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	15,725	44.92	$706,367.00	9,401	4
2025-09-30	Loumeau, Eric J	Officer	CHIEF LEGAL OFFICER	Direct	Sale	8,240	29.00	$238,960.00	9,088	4
2025-08-08	Renton, Hollings	Director	-	Direct	Sale	10,231	19.57	$200,220.67	4,965	4
2025-07-02	Renton, Hollings	Director	-	Direct	Sale	20,925	23.46	$490,900.50	4,965	4
2025-06-18	Renton, Hollings	Director	-	Direct	Sale	3,015	23.97	$72,269.55	4,965	4
2025-06-18	Fenton, Dennis M	Director	-	Direct	Sale	3,015	23.97	$72,269.55	4,965	4
2025-01-02	Ecor1, Capital, Llc, Node…	Director,TenPercentOwner	-	Indirect	Purchase	6,646	12.95	$86,065.70	7,880,094	4
2024-11-29	Renton, Hollings	Director	-	Direct	Sale	10,000	25.00	$250,000.00	1,950	4
2024-09-23	Lizzul, Paul F.	Officer	Chief Medical Officer	Direct	Sale	1,500	38.67	$58,005.00	15,398	4
2024-09-17	Loumeau, Eric J	Officer	CHIEF LEGAL OFFICER	Direct	Sale	3,780	38.41	$145,189.80	3,240	4
2024-09-16	Mulroy, Dennis	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	12,220	39.53	$483,056.60	4,744	4
2024-09-16	Lizzul, Paul F.	Officer	Chief Medical Officer	Direct	Sale	2,220	38.93	$86,424.60	15,398	4
2024-08-14	Ecor1, Capital, Llc	TenPercentOwner	-	Indirect	Purchase	273,972	36.50	$9,999,978.00	7,794,996	4
2024-08-14	Lizzul, Paul F.	Officer	Chief Medical Officer	Direct	Sale	2,000	40.00	$80,000.00	11,618	4
2024-07-18	Lizzul, Paul F.	Officer	Chief Medical Officer	Direct	Sale	1,500	35.00	$52,500.00	11,618	4
2024-07-15	Renton, Hollings	Director	-	Direct	Sale	10,000	30.74	$307,400.00	1,950	4
2024-06-21	Fenton, Dennis M	Director	-	Direct	Sale	1,950	23.17	$45,181.50	1,950	4
2024-06-18	Renton, Hollings	Director	-	Direct	Sale	1,950	23.16	$45,162.00	1,950	4
2024-05-22	Mulroy, Dennis	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,500	23.72	$35,580.00	964	4
2024-03-25	Faga, Daniel	Director,Officer	CEO	Direct	Sale	3,000	21.42	$64,260.00	749,087	4
2024-02-16	Loumeau, Eric J	Officer	CHIEF LEGAL OFFICER	Direct	Sale	5,000	25.00	$125,000.00	3,240	4
2024-01-30	Mulroy, Dennis	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,065	23.63	$72,425.95	964	4
2024-01-08	Faga, Daniel	Director,Officer	CEO	Direct	Sale	6,866	21.81	$149,747.46	898,027	4
2024-01-08	Lizzul, Paul F.	Officer	Chief Medical Officer	Direct	Sale	2,554	21.81	$55,702.74	10,118	4
2024-01-08	Loumeau, Eric J	Officer	Chief Legal Officer	Direct	Sale	2,305	21.81	$50,272.05	3,240	4
2024-01-08	Mulroy, Dennis	Officer	Chief Financial Officer	Direct	Sale	2,180	21.81	$47,545.80	4,029	4
2023-11-22	Loumeau, Eric J	Officer	Chief Legal Officer	Direct	Sale	882	14.19	$12,515.58	0	4
2023-09-18	Loumeau, Eric J	Officer	Chief Legal Officer	Direct	Sale	3,895	19.32	$75,251.40	882	4
2023-09-18	Mulroy, Dennis	Officer	Chief Financial Officer	Direct	Sale	3,895	19.32	$75,251.40	964	4
2023-09-14	Lizzul, Paul F.	Officer	Chief Medical Officer	Direct	Sale	2,105	19.48	$41,005.40	6,527	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

97.70%

Inst. Shares: 28,029,935

Shares Outstanding: 28,691,000

2025-12-31

101.30%

Inst. Shares: 29,131,235

Shares Outstanding: 28,758,000

2025-09-30

111.90%

Inst. Shares: 31,144,277

Shares Outstanding: 27,833,000

2025-06-30

124.56%

Inst. Shares: 35,884,638

Shares Outstanding: 28,810,000

2025-03-31

126.80%

Inst. Shares: 38,855,223

Shares Outstanding: 30,644,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	28,029,935	28,691,000	97.70%
2025-12-31	29,131,235	28,758,000	101.30%
2025-09-30	31,144,277	27,833,000	111.90%
2025-06-30	35,884,638	28,810,000	124.56%
2025-03-31	38,855,223	30,644,000	126.80%
2024-12-31	33,120,792	28,382,000	116.70%
2024-09-30	32,565,601	28,893,000	112.71%
2024-06-30	28,775,928	27,356,000	105.19%
2024-03-31	28,822,082	26,801,000	107.54%
2023-12-31	29,649,936	26,924,000	110.12%
2023-09-30	29,829,073	26,546,000	112.37%
2023-06-30	28,489,423	26,629,000	106.99%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

ANAPTYSBIO, INC (ANAB) — SEC Financial Statements & Analysis

ANAPTYSBIO, INC (ANAB) is a pharmaceutical preparations company, incorporated in DE. ANAPTYSBIO, INC trades on Nasdaq as: ANAB. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), ANAPTYSBIO, INC reported a 107.73% year-over-year revenue growth, a Debt-to-Equity ratio of 3.27x, a Price-to-Sales (P/S) ratio of 4.56x (TTM), a Price-to-Book (P/B) ratio of 83.22x (TTM), at a market cap of $1.06B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 107.73%
Debt To Equity: 3.27x
P/S TTM: 4.56x
P/B TTM: 83.22x
Market Cap: $1.06B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ANAPTYSBIO, INC in?

ANAPTYSBIO, INC (ANAB) operates in the Pharmaceutical Preparations industry.

What is ANAB's market cap?

ANAPTYSBIO, INC (ANAB) has a market capitalization of $1.06B as of 2026-03-31.

What exchange does ANAB trade on?

ANAPTYSBIO, INC (ANAB) trades on the Nasdaq.

Where is ANAPTYSBIO, INC incorporated?

ANAPTYSBIO, INC is incorporated in DE.

ANAPTYSBIO, INC

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

ANAPTYSBIO, INC (ANAB) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

ANAPTYSBIO, INC (ANAB) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.